Blar i ODA Open Digital Archive på forfatter "Byrne, Jude"

Viser treff 1-2 av 2

    • Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. 

      Grebely, Jason; Bruneau, Julie; Lazarus, Jeffrey; Dalgard, Olav; Bruggmann, Philip; Treloar, Carla; Hickman, Matthew; Hellard, Margaret; Roberts, Teri; Crooks, Levinia; Midgard, Håvard; Larney, Sarah; Degenhardt, Louisa; Alho, Hannu; Byrne, Jude; Dillon, John F; Feld, Jordan J; Foster, Graham; Goldberg, David E; Lloyd, Andrew R; Reimer, Jens; Robaeys, Geert; Torrens, Marta; Wright, Nat; Maremmani, Icro; Norton, Brianna L; Litwin, Alain H; Dore, Gregory J (International Journal of Drug Policy;47, Journal article; Peer reviewed, 2017-09)
      Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but ...

    • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial 

      Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B.; Bruggmann, Philip; Hajarizadeh, Behzad; Amin, Janaki; Bruneau, Julie; Hellard, Margaret; Litwin, Alain H.; Marks, Phillippa; Quiene, Sophie; Siriragavan, Sharmila; Applegate, Tanya L.; Swan, Tracy; Byrne, Jude; Lacalamita, Melanie; Dunlop, Adrian; Matthews, Gail V.; Powis, Jeff; Shaw, David; Thurnheer, Maria Christine; Weltmann, Martin; Kronborg, Ian; Cooper, Curtis; Feld, Jordan J.; Fraser, Chris; Dillon, John F.; Read, Phillip; Gane, Edward; Dore, Gregory J. (The lancet Gastroenterology & hepatology;3(3), Journal article; Peer reviewed, 2018-03)
      Background Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to ...